NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$11.49 +0.26% (+$0.03)
1M -0.95%
Market Cap $1.61B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
41 /100
Fair P/B 2.21x
P/S 26.98x
EV/EBITDA N/A
Growth
49 /100
Stable Book val. growth 18.40%
Rev. growth 9.09%
FCF growth N/A
Profitability
0 /100
Weak Net margin 672.16%
Op. margin 711.66%
FCF margin 783.30%
Quality
1 /100
Poor ROE 57.79%
ROA 46.66%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.65x
Debt/Equity 0.10x
Net debt/EBITDA N/A
Stability
33 /100
Unstable Rev. volatility 45.00%
EPS volatility 12.29%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Upcoming events
05 NOV
Earnings
Upcoming earnings report